All the news Showing 10 of 86 articles from: Treatment for people living with HIV and HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Improvements in HIV treatment and care have had no impact on rates of endstage liver disease among HIV-positive people with viral hepatitis Michael Carter / 01 September 2016 Incidence of endstage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the United States ... AbbVie 3D and 2D hepatitis C combos work well for people with HIV and HCV co-infection Liz Highleyman / 01 August 2016 AbbVie's paritaprevir-based 3D regimen for hepatitis C virus (HCV) genotype 1 and 2D regimen for genotype 4 were shown to be highly effective and well tolerated for HIV-positive people with HCV co-infection ... Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study Liz Highleyman / 21 July 2016 The once-daily co-formulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes in people with HIV/HCV co-infection and was safe and well tolerated in the ASTRAL-5 trial, according ... Does having HIV affect response to hepatitis C treatment? Liz Highleyman / 16 May 2016 A study from the US Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral (DAA) therapy for hepatitis C, while a Spanish study showed that ... Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection Liz Highleyman / 19 April 2016 A dual regimen of sofosbuvir plus velpatasvir was well tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic hepatitis C co-infection, according to results ... Starting HIV therapy associated with improvements in liver function, especially when viral load is suppressed Michael Carter / 21 March 2016 Starting antiretroviral therapy is associated with improvements in liver function in HIV-positive men with and without viral hepatitis co-infection, investigators from the United States report in the online edition of the Journal of ... Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals Liz Highleyman / 11 March 2016 Sofosbuvir/velpatasvir, a forthcoming combination that effectively treats all hepatitis C virus (HCV) genotypes, can be safely used with most boosted antiretrovirals for people with HIV and HCV co-infection, according to a study presented ... Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low Liz Highleyman / 26 February 2016 An interferon- and ribavirin-free regimen of sofosbuvir/ledipasvir (Harvoni) taken for just 6 weeks was enough to cure hepatitis C in HIV-positive people with recent hepatitis C virus (HCV) infection if their HCV viral ... Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... People with HIV and HCV co-infection achieve high HCV cure rates with grazoprevir/elbasvir Liz Highleyman / 16 November 2015 A dual combination of Merck's grazoprevir and elbasvir taken for 12 or 16 weeks cured most HIV-positive people with genotype 1, 4 or 6 hepatitis C virus (HCV) co-infection and was generally safe ... ← Prev1...23456...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive